Drug Type Peptide Conjugate Radionuclide, Cyclic Peptide, Therapeutic radiopharmaceuticals |
Synonyms 225Ac-RAYZ 6114, 225Ac-RAYZ6114 |
Target |
Action antagonists |
Mechanism EphA2 antagonists(Ephrin type-A receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Prostatic Cancer | Preclinical | United States | 25 May 2023 | |
| Prostatic Cancer | Preclinical | Japan | 25 May 2023 |





